DAFTAR PUSTAKA

Aran V, Victorino AP, Thuler LC, Ferreira CG. 2016. Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality. Elsevier.

Weng W, Feng J,Qin H, Ma Y, and Goel A. 2015. An Update on MiRNAs as Biological and Clinical Determinants in Colorectal Cancer: a bench-to-bedside approach. *Future Oncology* 11(12): 1791–1808.

Bailey CE, Hu CY, You YN, et al. 2015. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 2975-2010. *JAMA Surg* 150: 17-22

Burt R, and Neklason DW. 2005. Genetic testing for inherited colon cancer. *Gastroenterology* 128: 1696-1716

Fearon ER. 2011. Molecular genetics of colorectal cancer. *Ann Rev Pathol* 6: 470-507

Schneider BL, Kulesz-Martin M. Destructive cycles. 2004. The Role of Genomic Instability and Adaptation in Carcinogenesis. *Carcinogenesis* 25:2033-2044

Zhu B, Sun Y, Qi L, Zhong R, and Miao X. 2015. Dietary legume consumption reduces risk of colorectal cancer: evidence from a meta-analysis of cohort studies. *Sci Rep* 5: 8797

Herrinton LJ, Liu L, Levin TR, et al. 2012. Incidece and Mortality of Colorectal Adenocarcinoma in Persons with Inflammatory Bowel Disease from 1998 to 2010. *Gastroenterology* 143:382-389

Gonzalez CA and Riboli E. 2010. diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Eur J Cancer* 46: 2555-2562

Aalok Kumar HFK, Lim HJ, Renouf DJ, Woods R, Speers C, and Cheung Wy. 2012. Adjuvant chemotherapy (AC) use and outcomes in stage II colon cancer (CC) with and without poor prognostic features. *J Clin Oncol* 30

Andre T, Boni, Navarro M, et al. 2009 improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J CLin Oncol* 27: 3109-3116

Tournigand C, Andre T, Bonnetain F, et al. 2012. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. *J Clin Oncol* 30: 3353-3360

Sargent DJ, Yothers G, et al. 2014. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): a pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. *J Clin Oncol* 32: 5

Bartel DP. 2009. microRNA: target recognition and regulatory functions. *Cell* 136:215-233

Raisch J, Darfeuille-Michaud A, Nguyen HT. 2013. role of microRNAs in the immune system, inflammation and cancer. *World Journal Gastroenterology* 19:2985-2996

Wightman B, Ha I, Ruvkun G. 1993. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-14 mediated temporal pattern formation in C. elegans. *Cell* 75:855-862

Esquela-Kerscher A, Slack FJ. 2006. Oncomirs-microRNAs wih a role in cancer. *Nat Rev Cancer* 6:259-269

Altomare DF, Di Lena M, Giuratrabocchetta S. 2012. microRNA: future perspective in colorectal cancer. *Colorectal Dis* 14:133-134

Fearon ER, Volgestein B. 1990. A genetic model for colorectal tumorigenesis. *Cell* 61:759-767

Ahmed FE, Jeffries CD, Vos PW, et al. 2009. diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. *Cancer Genomics Proteomics* 6:281-295

Cheng H, Zhang I, Cogdell DE, et al. 2011. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. *PLos One* 6:e17745

Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. 2010. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. *International Journal of Cancer* 127:118-126

Pu XX, Huang DI, Guo HQ, et al. 2010. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. *Journal of Gastroenterology and Hepatology* 25:1674-1680

Ng EK, Iguchi H, Ochiya T. 2010. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. *Cancer Science* 101:2087-2092

Oue N, Anami K, Schetter AJ, Moehler M, Okayama H, Khan MA, Bowman ED, Mueller A, Schad A, Shimomura M, Hinoi T, Aoyagi K, Sasaki H, Okajima M, Ohdan H, Galle PR, Yasui W, Harris CC. 2014. High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. *Int J Cancer* 134: 1926-1934

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC. 2008. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. *JAMA* 299: 425-436

Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. Serum miR-21 as a diagnostic and

prognostic biomarker in colorectal cancer. *J Natl Cancer Inst* 105: 849-859

Clark JC, Thomas DM, Choong PF, Dass CR. 2007. RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. *Cancer Metastasis Rev* 26: 675-683 [

Stiegelbauer V, Perakis S, Deutsch A, Ling H, Gerger A, Pichler M. 2014. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. *World J. Gastroenterol* 20, 11727–11735

Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. 2014 Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. *Ann. Surg* 259, 735–743.

Hansen TF, Christensen RD, Andersen RF, Sørensen FB, Johnsson A, Jakobsen A. 2013. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. *Br. J. Cancer* 109, 1243–1251

Xing J, Wan S, Zhou F, Qu F, Li B, Myers RE, Fu X, Palazzo JP, He X, Chen Z, Yang H. 2012. Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. *Cancer Epidemiol. Biomark. Prev.* 21, 217–227.

Clark J, Grothey A Goldberg R. 2015. Systemic Chemotherapy for Nonoperable Metastatic Colorectal Cancer: Treatment Recommendations. UpToDate: Waltham, MA, USA, 2015

Abdullah M, Sudoyo AW, Utomo AR, Fauzi A, Rani AA. 2012. Molecular profile of colorectal cancer in Indonesia: is there another pathway? *Gastroenterology and Hepatology From Bed to Bench* 5(2): 71-78

Wang L, Qian L, Li X, Yan J. 2014. MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3. *Mol Med Rep* 10(1): 473-478

Kokki I, Papana A, Campbell H, Theodoratou E, 2013, Estimating the incidence of colorectal cancer in South East Asia. *Croat Med J*, 54: 532-540.

Kim JW, Shin MK, Kim BC, 2015, Clinicopathologic impacts of poorly differentiated cluster-based grading system in colorectal carcinoma. *J Korean Med Sci*, 30:16-23.

American Cancer Society. Colorectal Cancer Facts and Figures 2014-2016. Am Cancer Soc. 2012:1-25.

International Agency for Research on Cancer WHO. Fact Sheets by Population, Estimated Age-Standardise Incidence and Mortality Rates.; 2012. Diunduh dari: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Diakses terakhir: 17 November 2015.

Riwanto I, Hamami AH, Pieter J, Tjambolang T, Ahmadsyah I. Usus Halus, Appendiks, Kolon, dan Anorektum. Dalam: Buku Ajar Ilmu Bedah. Edisi ketiga. Jakarta: EGC; 2012:731-98.

Tanaka T, Tanaka M, Tanaka T, Ishigamori R. Biomarkers for Colorectal Cancer. Int J Mol Sci. 2010:3209-25.

Murray RK, Granner DK, Rodwell VW. Biokimia Harper. Edisi kedua puluh tujuh. Diterjemahkan oleh Brahm Udumbara dan Hartono Andry. (Maxine A. Papadakis M, Stephen J. McPhee M, Roni F. Zeiger M, eds.). Jakarta: EGC; 2006.

Kumar V, Abbas AK, Fausto N. Dasar Patologis Penyakit; Robbins & Cotran. Edisi ketujuh. Diterjemahkan oleh Hartono Andry. Jakarta: EGC; 2010.

Nair R, Resident S, Nayal B, Rao BHA. Carcinoembryonic antigen, C-reactive protein, and albumin as prognostic indicators in colorectal carcinomas. Int J Sci Res. 2015;5(2):1-10.

Yang K, Yang S, Liang W, Kuo Y, Lin J, et al. Carcinoembryonic antigen (CEA) level , CEA ratio , and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol J. 2013:1-9.

Fakih M, Padmanabhan A. CEA Monitoring in Colorectal Cancer. cancer Netw. 2006:1-12.

Phatology Harmony. Tumour Marker Bookmark. 2012. Diunduh dari: http://pathologyharmony.co.uk/. Diakses terakhir pada 26 Desember 2015.

Malati T. Tumour Markers : An Overview. Indian J Clin Biochem. 2007;22(2):17-31.

Duffy MJ. Carcinoembryonic Antigen as a Marker for Colorectal Cancer: is it clinically useful?. Clin Chem. 2001;47(4):624-30.

Sack J, Rothman JM. Colorectal Cancer : Natural History and Management. Pennsylvania: turner white communication; 2000.

Polat E, Duman U, Atici AE, Reyhan E, Dalgic T. Diagnostic value of preoperative serum carcinoembryonic antigen